MINNEAPOLIS, and BEVERLY HILLS, Calif., Aug. 5, 2014 /PRNewswire/ -- ViaDerma, Inc. (OTCQB: VDRM), a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development, and The Brewer Group, Inc. (TBG), a diversified global investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma's business development and marketing efforts at home and abroad to grow interest in ViaDerma's patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of active ingredients and immediate relief of symptoms.
ViaDerma licenses products in fields of medicine ranging from infectious disease treatments to stem-cell therapy. Pharmaceutical companies seeking more efficient methods for delivering their products to patients will have new access to solutions worldwide, as The Brewer Group, Inc. and ViaDerma, Inc. leverage TBG's vast network to pave the way for new strategic business alliances and expand the range of the breakthrough rapid delivery of nutrients and medicines using ViaDerma's technology.
ViaDerma continues to develop new applications for its trade-secret Rapid Active Ingredient Delivery System (RAIDS), and founder Dr. Christopher Otiko emphasizes its extreme versatility. "The speed of the RAIDS method for pharmaceutical distribution and the wide variety of products that can utilize it will allow medical professionals and general consumers alike to benefit from faster treatment," Dr. Otiko said. "Products using RAIDS are at the forefront of medical sophistication and nearly any drug that medical professionals can administer as a pill can utilize RAIDS for quicker delivery, from pain relievers to cosmetics. As ViaDerma, Inc. expands, our par
|SOURCE ViaDerma, Inc.|
Copyright©2014 PR Newswire.
All rights reserved